Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374813 | 0.86 | CPA3 (0.43) | CPA3FOLH1NAALAD2 | |
| SCHEMBL7610535 | 0.86 | CPA3 (0.53) | CPA3ALDH1A1CYP2D6CYP1A2TSHR | |
| SCHEMBL1374283 | 0.78 | CPA3 (0.59) | CPA3ALDH1A1CYP2D6CYP1A2TSHR | |
| SCHEMBL9322167 | 0.77 | KEAP1 (0.43) | CPA3ALDH1A1CYP2D6CYP1A2TSHR | |
| SCHEMBL1373565 | 0.76 | CPA3 (0.56) | CPA3CYP1A2FOLH1NAALAD2MAPK1 | |
| SCHEMBL19506060 | 0.74 | MMP2 (0.46) | CYP1A2TSHRCYP2C19HSD17B10 | |
| SCHEMBL1374881 | 0.74 | CPA3 (0.54) | CPA3FOLH1MAPK1 | |
| SCHEMBL27852451 | 0.73 | CYP2C19 (0.39) | CPA3CYP1A2TSHRCYP2C19POLB | |
| SCHEMBL5682990 | 0.73 | MMP12 (0.44) | CPA3CYP1A2TSHRCYP2C19POLB | |
| SCHEMBL27166774 | 0.73 | APAF1 (0.42) | ALDH1A1CYP1A2TSHRKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002514185-A | — | — | 2002-05-14 | — | — | JP | claimed |
| JP-2001521512-A | — | — | 2001-11-06 | — | — | JP | claimed |
| EP-1019369-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1998045257-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2025-04-24 | — | — | US | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2025-04-03 | — | — | US | disclosed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | disclosed |
| WO-2003035688-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | NOVARTIS PHARMA GMBH (AT) | 2003-05-01 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1019369-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1998045257-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CPA3 525/4885ALDH1A1 2843/4885CYP2D6 4633/4885 |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CPA3 525/4885ALDH1A1 2843/4885CYP2D6 4633/4885 |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | CPA3 193/4885ALDH1A1 736/4885CYP2D6 3489/4885 |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | VHL, PC, NPC1 | CPA3 1830/4885ALDH1A1 1234/4885CYP2D6 2730/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | CPA3 217/4885ALDH1A1 3263/4885CYP2D6 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.